drugset
drugset / Trial / NCT05895864

Utidelone Treated for the Recurrent or Metastatic Urothelial Carcinoma

NCT05895864 ↗

Phase 2 Unknown 34 enrolled Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NaSingle-groupOpen-labelTreatment

Summary

This study is a open-label, multicenter, phase II study to evaluate the efficacy and safety of utidelone in the recurrent or metastatic urothelial carcinoma after prior chemotherapy.

Timeline

Start
2023-06-07
Primary completion
2024-12-31
Completion
2025-12-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Epothilone D Small molecule 35 mg/m2 Intravenous

Indications

urothelial carcinoma